Blaszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A
Cancers (Basel). 2025; 17(2).
PMID: 39858010
PMC: 11764116.
DOI: 10.3390/cancers17020228.
Hu K, Wu Y, Huang Y, Zhou M, Wang Y, Huang X
Breast Cancer Res. 2025; 27(1):6.
PMID: 39800743
PMC: 11725188.
DOI: 10.1186/s13058-025-01959-1.
Lien H, Yu H, Yu W, Lin S, Chen T, Chen I
Breast Cancer Res. 2024; 26(1):130.
PMID: 39256881
PMC: 11385830.
DOI: 10.1186/s13058-024-01888-5.
Dziuba I, Gawel A, Tyrna P, Machtyl J, Olszanecka M, Pawlik A
Int J Mol Sci. 2023; 24(7).
PMID: 37047791
PMC: 10095369.
DOI: 10.3390/ijms24076819.
Yan C, Li Q, Sun Q, Yang L, Liu X, Zhao Y
Int J Nanomedicine. 2023; 18:1195-1218.
PMID: 36926681
PMC: 10013574.
DOI: 10.2147/IJN.S401570.
AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism.
Vitaliti A, Roccatani I, Iorio E, Perta N, Gismondi A, Chirico M
Cell Oncol (Dordr). 2022; 46(1):93-115.
PMID: 36454513
PMC: 9947069.
DOI: 10.1007/s13402-022-00738-w.
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells.
Sterken B, Ackermann T, Muller C, Zuidhof H, Kortman G, Hernandez-Segura A
NPJ Breast Cancer. 2022; 8(1):11.
PMID: 35042889
PMC: 8766495.
DOI: 10.1038/s41523-021-00372-z.
Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
Shin S, Cho H, Das R, Gil-Henn H, Ramakrishnan S, Al Bayati A
Cells. 2021; 10(11).
PMID: 34831127
PMC: 8616280.
DOI: 10.3390/cells10112904.
KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance.
Arafah M, Ouban A, Ameer O, Quek K
Breast Cancer (Auckl). 2021; 15:11782234211016977.
PMID: 34158798
PMC: 8186110.
DOI: 10.1177/11782234211016977.
miR-155 promotes proliferation and epithelial-mesenchymal transition of MCF-7 cells.
Liu X, Li Y, Li Z, Hou T
Exp Ther Med. 2021; 21(3):218.
PMID: 33500705
PMC: 7818536.
DOI: 10.3892/etm.2021.9650.
Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?.
Schmidt G, Solomayer E, Bohle R, Gerlinger C, Radosa J, Endrikat J
J Cancer Res Clin Oncol. 2020; 146(8):2109-2116.
PMID: 32266539
DOI: 10.1007/s00432-020-03210-0.
MicroRNA-181c Suppresses the Biological Progression of Osteosarcoma via Targeting SMAD7 and Regulating Transforming Growth Factor-β (TGF-β) Signaling Pathway.
Fu Y, Tang Y, Wang J, Guo Z
Med Sci Monit. 2019; 25:4801-4810.
PMID: 31251735
PMC: 6612243.
DOI: 10.12659/MSM.916939.
Differential expression and clinical significance of epithelial-mesenchymal transition markers among different histological types of triple-negative breast cancer.
Zhou S, Sun X, Yu L, Zhou R, Li A, Li M
J Cancer. 2018; 9(3):604-613.
PMID: 29483966
PMC: 5820928.
DOI: 10.7150/jca.19190.
Prognostic significance of expression of epithelial-mesenchymal transition driver brachyury in breast cancer and its association with subtype and characteristics.
Lee K, Kim E, Yun J, Park Y, DO S, Chae S
Oncol Lett. 2018; 15(1):1037-1045.
PMID: 29399164
PMC: 5772917.
DOI: 10.3892/ol.2017.7402.
UNC0638, a G9a inhibitor, suppresses epithelial‑mesenchymal transition‑mediated cellular migration and invasion in triple negative breast cancer.
Liu X, Zhou L, Hu J, Liu L, Wan H, Zhang X
Mol Med Rep. 2017; 17(2):2239-2244.
PMID: 29207160
PMC: 5783465.
DOI: 10.3892/mmr.2017.8190.
Endothelial‑to‑mesenchymal transition in human idiopathic dilated cardiomyopathy.
Xie Y, Liao J, Yu Y, Guo Q, Yang Y, Ge J
Mol Med Rep. 2017; 17(1):961-969.
PMID: 29115553
PMC: 5780177.
DOI: 10.3892/mmr.2017.8013.
Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma.
Zhang X, Li Q, Zhao H, Ma L, Meng T, Qian J
Oncotarget. 2017; 8(35):59086-59102.
PMID: 28938620
PMC: 5601716.
DOI: 10.18632/oncotarget.19175.
E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis.
Liu J, Feng C, Deng M, Ge D, Liu D, Mi J
World J Surg Oncol. 2017; 15(1):139.
PMID: 28764784
PMC: 5539617.
DOI: 10.1186/s12957-017-1210-8.
associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A
J Pathol Clin Res. 2017; 3(2):123-138.
PMID: 28451461
PMC: 5402179.
DOI: 10.1002/cjp2.69.
GD2 expression in breast cancer.
Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T
Oncotarget. 2017; 8(19):31592-31600.
PMID: 28415563
PMC: 5458232.
DOI: 10.18632/oncotarget.16363.